【摘 要】
：
Cyclodextrin metal-organic framework(CD-MOF)as a highly porous supramolecular carrier could be one of the solutions to the insolubility of isosteviol(STV).The solubility of STV was lower than 20.00 ng/mL at pH 1.0 and pH 4.5,whilst its solubility increase
【机 构】
：
Anhui University of Traditional Chinese Medicine,Anhui 230000,China;Center for Drug Delivery Systems
论文部分内容阅读
Cyclodextrin metal-organic framework(CD-MOF)as a highly porous supramolecular carrier could be one of the solutions to the insolubility of isosteviol(STV).The solubility of STV was lower than 20.00 ng/mL at pH 1.0 and pH 4.5,whilst its solubility increased to 20,074.30 ng/mL at pH 6.8 and 129.58 ng/mL in water with a significant pH-dependence.The in vitro release profiles of STV from STV@CD-MOF(0.5∶1)were pH-independent in distinct pH media and closed to be thoroughly released but no such release profiles were observed for STV@CD-MOF(1∶1)owing to nanoclusters formation.The bioavailability of STV@CD-MOF(1∶1)in rats was 8.67-fold higher than that of STV,and was 1.32-and 1.27-fold higher than that of STV@CD and STV@CD-MOF(0.5∶1).Our results indicated that the inclusion mechanism played a primary role when STV in CD-MOF was at a low loading ratio,while the increasement in bioavailability at a high loading ratio,which was attributed to the nanocluster mech-anism.This was confirmed by molecular simulation.In conclusion,CD-MOF is a promising system for STV loading,overcoming the insolubility and to improve the bioavailability of this natural compound.
其他文献
Lipid-based formulations(LBFs)have demonstrated a great potential in enhancing the oral absorption of poorly water-soluble drugs.However,construction of in vitro and in vivo correlations(IVIVCs)for LBFs is quite challenging,owing to a complex in vivo proc
Three-dimensional printing is a technology that prints the products layer-by-layer,in which materials are deposited according to the digital model designed by computer aided design(CAD)soft-ware.This technology has competitive advantages regarding product
COVID-19 pandemic caused by SARS-CoV-2 infection severely threatens global health and economic development.No effective antiviral drug is currently available to treat COVID-19 and any other human coronavirus infections.We report herein that a macrolide an
Amorphous solid dispersions(ASDs)are popular for enhancing the solubility and bioavailability of poorly water-soluble drugs.Various approaches have been employed to produce ASDs and novel tech-niques are emerging.This review provides an updated overview o
Pharmaceutical cocrystals are multicomponent systems in which at least one component is an active pharmaceutical ingredient and the others are pharmaceutically acceptable ingredients.Cocrystal-lization of a drug substance with a coformer is a promising an
Pulmonary administration route has been extensively exploited for the treatment of local lung diseases such as asthma,chronic obstructive pulmonary diseases and respiratory infections,and systemic diseases such as diabetes.Most inhaled medicines could be
Aberrant activation of NLRP3 inflammasome in colonic macrophages strongly associates with the occurrence and progression of ulcerative colitis.Although targeting NLRP3 inflammasome has been considered to be a potential therapy,the underlying mechanism thr
Solid tumors always exhibit local hypoxia,resulting in the high metastasis and inertness to chemotherapy.Reconstruction of hypoxic tumor microenvironment(TME)is considered a potential ther-apy compared to directly killing tumor cells.However,the insuffici
Parkinson\'s disease(PD)is the second most common neurodegenerative disease,but none of the current treatments for PD can halt the progress of the disease due to the limited understanding of the pathogenesis.In PD development,the communication between t
Malaria still threatens global health seriously today.While the current discoveries of antima-larials are almost totally focused on single mode-of-action inhibitors,multi-targeting inhibitors are highly desired to overcome the increasingly serious drug re